Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-26T21:48:49.679Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of metformin on fertilisation of bovine oocytes and early embryo development: possible involvement of AMPK3-mediated TSC2 activation

Published online by Cambridge University Press:  22 July 2013

Olympia Pikiou ,
Anna Vasilaki ,
George Leondaritis ,
Nikos Vamvakopoulos  and
Ioannis E. Messinis
Olympia Pikiou
Affiliation:
Department of Obstetrics & Gynecology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Anna Vasilaki
Affiliation:
Laboratory of Pharmacology, Department of Basic Sciences, Faculty of Medicine, University of Thessaly, Larissa, Greece.
George Leondaritis
Affiliation:
Laboratory of Pharmacology, Department of Basic Sciences, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Nikos Vamvakopoulos
Affiliation:
Laboratory of Biology, Department of Basic Sciences, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Ioannis E. Messinis*
Affiliation:
Department of Obstetrics and GynecologyUniversity of Thessaly Medical School 10 Larissa, Greece
*
All correspondence to: Ioannis E. Messinis. Department of Obstetrics and GynecologyUniversity of Thessaly Medical School 10 Larissa, Greece Tel: +30 2413502795. Fax: +30 2413501019. e-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

Studies on bovine oocytes have revealed that the activation of adenosine monophosphate activated protein kinase (AMPK) by millimolar concentrations of metformin controls nuclear maturation. Tuberous sclerosis complex 2 (TSC2) has been identified as a downstream target of AMPK. The objective of this study was to investigate the effects of addition of low concentrations of metformin (1 nM to 10 μM) on the percentage of cultured cumulus–oocyte complexes (COC) giving rise to cleavage-stage embryos and AMPK-mediated TSC2 activation. Metformin was supplemented either throughout in vitro embryo production (IVP) or only during in vitro fertilization (IVF). COC were matured in vitro, inseminated, and presumptive zygotes cultured for a further 72 h post insemination before the percentage of COC that gave rise to zygotes and early embryo development was assessed. The presence of TSC2 in bovine embryos and its possible AMPK-induced activation were assessed by immunocytochemistry. Metformin had a dose-dependent effect on the numbers of cultured COC that gave rise to embryos. Drug treatment either throughout IVP or only during IVF decreased the percentage of ≥8-cell embryos (1 μM, P < 0.05; 10 μM, P < 0.01; and 0.1 μM, 10 μM, P < 0.01, respectively) and increased the percentage of 2-cell embryos (10 μM, P < 0.01 and P < 0.05 respectively). The percentage of cultured COC that gave rise to zygotes was not affected by metformin. TSC2 is expressed in early embryos. Metformin (10 μM) either throughout IVP or during IVF only, increased AMPK-induced PhosphoS1387-TSC2 immunoreactivity (P < 0.01) and this increase corresponded to the total TSC2 protein levels expressed in cells. Our results suggest that there is a dose-dependent negative effect of metformin on the ability of oocytes to cleave following insemination, possibly mediated through an AMPK-induced activation of TSC2.

Keywords

Cleavage rateEarly embryosIn vitro cultureMetforminTSC2
Type
Research Article
Information
Zygote , Volume 23 , Issue 1 , February 2015 , pp. 58 - 67
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adamiak, S.J., Powell, K., Rooke, J.A., Webb, R. & Sinclair, K.D. (2006). Body composition, dietary carbohydrates and fatty acids determine post-fertilisation development of bovine oocytes in vitro. Reproduction 131, 247–58.Google Scholar
Adhikari, D., Flohr, G., Gorre, N., Shen, Y., Yang, H., Lundin, E., Lan, Z., Gambello, M.J. & Liu, K. (2009). Disruption of Tsc2 in oocytes leads to overactivation of the entire pool of primordial follicles. Mol. Hum. Reprod. 15, 765–70.Google Scholar
Bai, X. & Jiang, Y. (2010). Key factors in mTOR regulation. Cell. Mol. Life Sci. 67, 239–402.CrossRefGoogle ScholarPubMed
Bailey, C.J. (1997). Metformin and its role in the management of type II diabetes. Curr. Opin. Endocrinol. Diabetes 4, 40–7.CrossRefGoogle Scholar
Bilodeau-Goeseels, S., Sasseville, M., Guillemette, C. & Richard, F.J. (2007). Effects of adenosine monophosphate-activated kinase activators on bovine oocyte nuclear maturation in vitro. Mol. Reprod. Dev. 74, 1021–34.CrossRefGoogle ScholarPubMed
Corradetti, M.N., Inoki, K., Bardeesy, N., DePinho, R.A. & Guan, K.L. (2004). Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz–Jeghers syndrome. Genes Dev. 18, 1533–8.Google Scholar
Downs, S.M., Hudson, E.R. & Hardie, D.G. (2002). A potential role for AMP-activated protein kinase in meiotic induction in mouse oocytes. Dev. Biol. 245, 200–12.Google Scholar
Eng, G.S., Sheridan, R.A., Wyman, A., Chi, M.M.Y., Bibee, K.P., Jungheim, E.S. & Moley, K.H. (2007). AMP kinase activation increases glucose uptake, decreases apoptosis and improves pregnancy outcome in embryos exposed to high IGF-I concentrations. Diabetes 56, 2228–34.Google Scholar
Gao, X. & Pan, D. (2001). TSC1 and TSC2 tumor suppressors antagonize insulin signalling in cell growth. Genes Dev. 15, 1383–92.CrossRefGoogle ScholarPubMed
Goossens, K., Vandaele, L., Wydooghe, E., Thys, M., Dewulf, J., Peelman, L.J. & Van Soom, A. (2011). The importance of adequate fixation for immunofluorescent staining of bovine embryos. Reprod. Domest. Anim. 46, 1098–103.Google Scholar
Guertin, D.A. & Sabatini, D.M. (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9–22.Google Scholar
Gwinn, DM., Shackelford, D.B., Egan, D.F., Mihaylova, MM., Mery, A., Vasquez, D.S., Turk, B.E. & Shaw, R.J. (2008). AMPK phosphorylation of Raptor mediates a metabolic checkpoint. Cell 30, 214–26.Google ScholarPubMed
Hardie, D.G. & Carling, D. (1997). The AMP-activated protein kinase: fuel gauge of the mammalian cell? Eur. J. Biochem. 246, 259–73.CrossRefGoogle ScholarPubMed
Hatziefthimiou, A., Kiritsi, M., Kiropoulou, C., Vasilaki, A., Sakellaridis, N. & Molyvdas, P.A. (2009). Regional differences in the modulatory role of the epithelium in sheep airway. Clin. Exp. Pharmacol. Physiol. 36, 668–74.CrossRefGoogle ScholarPubMed
Hazeleger, N.L., Hill, DJ., Stubbings, R.B. & Walton, J.S. (1995). Relationship of morphology and follicular fluid environment of bovine oocytes to their developmental potential in vitro. Theriogenology 43, 509–22.CrossRefGoogle ScholarPubMed
Hong, S.G., Jang, G., Oh, H.J., Koo, O.J., Park, J.E., Park, H.J., Kang, S.K. & Lee, B.C. (2009). The effects of brain-derived neurotrophic factor and metformin on in vitro developmental competence of bovine oocytes. Zygote 17, 187–93.CrossRefGoogle ScholarPubMed
Hundal, R.S. & Inzucchi, S.E. (2003). Metformin: new understandings, new uses. Drugs 63, 1879–94.CrossRefGoogle ScholarPubMed
Inoki, K., Zhu, T. & Guan, K. (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577–90.CrossRefGoogle ScholarPubMed
Ito, N. & Rubin, G.M. (1999). Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 96, 529–39.CrossRefGoogle ScholarPubMed
Karttunen, P., Uusitupa, M. & Lamminsivu, U. (1983). The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained release preparation. Int. J. Clin. Pharmacol. 21, 31–6.Google Scholar
Kwong, W.Y., Adamiak, SJ., Gwynn, A., Singh, R. & Sinclair, K.D. (2010). Endogenous folates and single-carbon metabolism in the ovarian follicle, oocyte and pre implantation embryo. Reproduction 139, 1–12.CrossRefGoogle ScholarPubMed
Leverve, X.M., Guigas, B., Detaille, D., Batandier, C., Koceir, EA., Chauvin, C., Fontaine, E. & Wiernsperger, N.F. (2003). Mitochondrial metabolism and type 2 diabetes: a specific target for metformin. Diabetes Metab. 29, 6588–94.Google Scholar
Lord, J.M., Flight, I.H.K. & Norman, R.J. (2003). Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327, 951–5.CrossRefGoogle ScholarPubMed
Luo, Z., Zang, M. & Guo, W. (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 6, 457–70.Google Scholar
Manning, B.D. & Cantley, L.C. (2003). Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 28, 573–6.Google Scholar
Matthaei, S., Hamann, A., Klein, H.H., Benecke, H., Kreymann, G., Flier, JS. & Greten, H. (1991). Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 40, 850–7.CrossRefGoogle ScholarPubMed
Mayes, M.A., Laforest, M.F., Guillemette, C., Gilchrist, R.B. & Richard, F.J. (2007). Adenosine 5’ monophosphate kinase-activated protein kinase (PRKA). activators delay meiotic resumption in porcine oocytes. Biol. Reprod. 76, 589–97.Google Scholar
Meric-Bernstam, F. & Gonzalez-Angulo, A. (2009). Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27, 2278–87.Google Scholar
Musi, N., Hirshman, M.F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J.M., Ljunqvist, O., Efendic, S., Moller, D.E., Thorell, A. & Goodyear, L.J. (2002). Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51, 2074–81.Google Scholar
Nardo, L.G. & Rai, R. (2001). Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol. Endocrinol. 15, 373–80.Google Scholar
Potter, C.J. & Xu, T. (2001). Mechanisms of size control. Curr Opin Genet Dev 11, 279–477.Google Scholar
Sabatini, D.M. (2006). mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6, 729–34.Google Scholar
Sancak, Y., Thoreen, C.C., Peterson, T.R., Lindquist, R.A., Kang, S.A., Spooner, E., Carr, S.A. & Sabatini, D.M. (2007). PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25, 903–15.CrossRefGoogle ScholarPubMed
Sancak, Y., Peterson, T.R., Shaul, Y.D., Lindquist, R.A., Thoreen, C.C., Bar-Peled, L. & Sabatini, D.M. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496–501.Google Scholar
Shackelford, D.B. & Shaw, R.J. (2009). The LKB1–AMPK pathway: metabolism and growth control in tumour suppression. Nat. Rev. Cancer 9, 563–75.CrossRefGoogle ScholarPubMed
Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A. & Cantley, L.C. (2004). The LKB1 tumor suppressor negatively regulates mTOR signalling. Cancer Cell 6, 91–9.Google Scholar
Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., DePinho, R.A., Montminy, M. & Cantley, L.C. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642–6.Google Scholar
Stapleton, D., Mitchelhill, KI., Gao, G., Widmer, J., Michell, B.J., Teh, T., House, C.M., Fernandez, S., Cox, T., Witters, L.A. & Kemp, B.E. (1996). Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271, 611–4.Google Scholar
Stojkovic, M., Machado, SA., Stojkovic, P., Zakhartchenko, V., Hutzler, P., Goncalves, P.B. & Eckhard, W. (2001). Mitochondrial distribution and adenosine triphosphate content of bovine oocytes before and after in vitro maturation: correlation with morphological criteria and developmental capacity after in vitro fertilization and culture. Biol. Reprod. 64, 904–9.CrossRefGoogle ScholarPubMed
Tapon, N., Ito, N., Dickson, B.J., Treisman, J.E. & Hariharan, I.K. (2001). The Drosophila tuberous sclerosis gene homologs restrict cell growth and cell proliferation. Cell 105, 345–55.Google Scholar
Tosca, L., Froment, P., Solnais, P., Ferre, P., Foufelle, F. & Dupont, J. (2005). Adenosine 5’ monophosphate-activated protein kinase regulates progesterone secretion in rat granulosa cells. Endocrinology 146, 4500–13.Google Scholar
Tosca, L., Solnais, P., Ferre, P., Foufelle, F. & Dupont, J. (2006a). Metformin-induced stimulation of adenosine 5′ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol. Reprod. 75, 342–51.Google Scholar
Tosca, L., Crochet, S., Ferre, P., Foufelle, F., Tesseraud, S. & Dupont, J. (2006b). AMP activated protein kinase activation modulates progesterone secretion in granulosa cells from hen preovulatory follicles. J. Endocrinol. 190, 85–97Google Scholar
Tosca, L., Uzbekova, S., Chabrolle, C. & Dupont, J. (2007). Possible role of 5′ AMP activated protein kinase in the metformin-mediated arrest of bovine oocytes at the germinal vesicle stage during in vitro maturation. Biol. Reprod. 77, 452–65.CrossRefGoogle ScholarPubMed
Towler, M.C. & Hardie, D.G. (2007). AMP-activated protein kinase in metabolic control and insulin signalling. Circ. Res. 100, 328–41.Google Scholar
Vasilaki, A., Papadaki, T., Notas, G., Kolios, G., Mastrodimou, N., Hoyer, D., Tsilimbaris, M., Kouroumalis, E., Pallikaris, I. & Thermos, K. (2004). Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. Invest. Ophthalmol. Vis. Sci. 45, 1499–506.CrossRefGoogle ScholarPubMed
Wullschleger, S., Loewith, R. & Hall, M.N. (2006). TOR signalling in growth and metabolism. Cell 124, 471–84.Google Scholar
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J. & Moller, D.E. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–74.Google Scholar